TIAA CREF Investment Management’s Neurocrine Biosciences NBIX Stock Holding History
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2019
Q1 | $46.2M | Buy |
524,465
+293,210
| +127% | +$25.8M | 0.03% | 427 |
|
2018
Q4 | $16.5M | Sell |
231,255
-95,643
| -29% | -$6.83M | 0.01% | 717 |
|
2018
Q3 | $40.2M | Buy |
326,898
+4,655
| +1% | +$572K | 0.03% | 506 |
|
2018
Q2 | $31.7M | Buy |
322,243
+14,425
| +5% | +$1.42M | 0.02% | 578 |
|
2018
Q1 | $25.5M | Sell |
307,818
-44,298
| -13% | -$3.67M | 0.02% | 653 |
|
2017
Q4 | $27.3M | Buy |
352,116
+44,642
| +15% | +$3.46M | 0.02% | 641 |
|
2017
Q3 | $18.8M | Sell |
307,474
-21,561
| -7% | -$1.32M | 0.01% | 787 |
|
2017
Q2 | $15.1M | Buy |
329,035
+57,371
| +21% | +$2.64M | 0.01% | 895 |
|
2017
Q1 | $11.8M | Buy |
271,664
+39,717
| +17% | +$1.72M | 0.01% | 1014 |
|
2016
Q4 | $8.98M | Buy |
231,947
+49,982
| +27% | +$1.93M | 0.01% | 1194 |
|
2016
Q3 | $9.22K | Buy |
181,965
+8,775
| +5% | +$444 | 0.01% | 1178 |
|
2016
Q2 | $7.87M | Sell |
173,190
-178,008
| -51% | -$8.09M | 0.01% | 1218 |
|
2016
Q1 | $13.9M | Buy |
351,198
+24,842
| +8% | +$983K | 0.01% | 885 |
|
2015
Q4 | $18.5M | Buy |
326,356
+21,179
| +7% | +$1.2M | 0.01% | 785 |
|
2015
Q3 | $12.1M | Buy |
305,177
+13,698
| +5% | +$545K | 0.01% | 946 |
|
2015
Q2 | $13.9M | Buy |
291,479
+5,579
| +2% | +$266K | 0.01% | 939 |
|
2015
Q1 | $11.4M | Buy |
285,900
+17,523
| +7% | +$696K | 0.01% | 1060 |
|
2014
Q4 | $6M | Sell |
268,377
-33,034
| -11% | -$738K | ﹤0.01% | 1499 |
|
2014
Q3 | $4.72M | Sell |
301,411
-7,351
| -2% | -$115K | ﹤0.01% | 1659 |
|
2014
Q2 | $4.58M | Buy |
308,762
+14,726
| +5% | +$219K | ﹤0.01% | 1750 |
|
2014
Q1 | $4.73M | Buy |
294,036
+7,511
| +3% | +$121K | ﹤0.01% | 1653 |
|
2013
Q4 | $2.68M | Hold |
286,525
| – | – | ﹤0.01% | 2074 |
|
2013
Q3 | $3.24M | Sell |
286,525
-7,318
| -2% | -$82.8K | ﹤0.01% | 1900 |
|
2013
Q2 | $3.93M | Buy |
+293,843
| New | +$3.93M | ﹤0.01% | 1695 |
|